Source ForPressRelease.com

Molbio Diagnostics, a leading player in point of care diagnostics has announced its partnership with Finnish innovation leader, Testi Technologies, to manufacture its flagship product PROMILLESS - a saliva-based diagnostics test to measure body alcohol content.



According to the World Health Organization, alcohol consumption contributes to 3 million deaths each year globally as well as to the disabilities and poor health of millions of people. The harmful use of alcohol is responsible for 5.1% of the global burden of disease.



PROMILLESS, an easy to use, low cost, SALIVA based self-diagnostics test that has been developed together with VTT (Technical Research Centre of Finland) is a CE approved class 1 device that is patented worldwide. The self-test alcohol strip recognizes alcohol content from saliva and determines if the alcohol content is above or below the indicated threshold level. This will help us enjoy life responsibly and with reliable information we can make the right choices. The self-test will be available over the counter for use by consumers and law enforcement.



Testi Technologies Oy, a Finnish innovation leader, specializes in developing groundbreaking saliva-based enzymatic tests. Collaborating with VTT Finland, they have pioneered "smart" enzymatic ink, propelling their flagship product, the "Promilless" alcohol content test, to near a million sales and earning EU Class I medical device registration.



Molbio diagnostics, a pioneer in revolutionary point of care diagnostics, will strengthen its commitment to providing accessible healthcare solutions by developing a strategic collaboration with Testi Technologies in the areas of technical development, manufacturing, marketing, sales and promotion of an array of diagnostic products.



"This partnership unites Testi Technologies' innovation in enzymatic test technology with Molbio Diagnostics™ technological strength, production capabilities and extensive global network. Together, we are set to revolutionize healthcare diagnostics, blending our strengths to offer advanced, accessible solutions. This collaboration is a powerful step towards making a significant impact on global health," says Mr. Tommi Vaskivuo, Chairman, Testi Technologies Ltd.



Broadening its scope, Testi Technologies is venturing into both human and pet healthcare markets with a forthcoming saliva-based glucose test. This expansion is part of a well-structured product roadmap, underlining Testi Technologies' commitment to revolutionizing healthcare diagnostics through a series of innovative enzymatic medical tests.



Under the current agreement, Molbio will have the rights to commercialize, market and sell PROMILLESS under its own brand name globally.



Mr. Sriram Natarajan, Chief Executive Officer of Molbio Diagnostics Pvt. Ltd says, "We are delighted to be a joint development, manufacturing and go to market partner of Testi Technologies. Their non-invasive enzymatic testing technology enables simple, rapid and accurate detection of analytes in saliva, by just touching the test stick to tongue. The current test for alcohol, the upcoming test for glucose and many more human and veterinary tests in the pipeline will prove to be revolutionary."